HVTN 056

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a CTL Multi-Epitope Peptide HIV Vaccine Formulated With RC529-SE, With or Without GM-CSF, in Healthy, HIV-1 Uninfected Adult Participants

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network (HVTN), Wyeth April 01, 2004
MEP Env, gag A, B, C, J
MEP Protein
USA 96